FDA skeptical of Marqibo data

An FDA review of Marqibo vincristine from Enzon (ENZN) and Inex (TSE:IEX) highlighted several regulatory and scientific flaws in the companies' application for accelerated approval to treat relapsed, aggressive non-Hodgkin's lymphoma (NHL). The Oncologic Drugs Advisory Committee

Read the full 372 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE